The race for a coronavirus vaccine heats up
The race for a coronavirus vaccine heats up
Biotech shares, led by AstraZeneca, are lifted in the race to come up with a coronavirus vaccine.
28 Aug 2020
Profit from the fast growth of the haircare industry
Profit from the fast growth of the haircare industry
Our society has become much more image-conscious, while new consumers worldwide want to look good too. From shampoos to new potential cures for baldne…
6 Aug 2020
Which Covid-19 vaccines look likely to be the best bets?
Which Covid-19 vaccines look likely to be the best bets?
The race to produce a treatment to prevent Covid-19 has hundreds of entrants. How should investors approach it? Matthew Partridge reports.
24 Jul 2020
Syncona: a biotech trust that's going for a song
Syncona: a biotech trust that's going for a song
Syncona is an investment trust that invests in promising, privately-held biotechnology companies. It looks too cheap.
15 Jun 2020
AstraZeneca mulls €240bn mega-merger with Gilead Sciences
AstraZeneca mulls €240bn mega-merger with Gilead Sciences
Pharma firm AstraZeneca is considering a merger with US peer Gilead Sciences to create a company with a market value of $240bn.
11 Jun 2020
The race to defeat the superbugs has just begun
The race to defeat the superbugs has just begun
Drug-resistant bacteria are far more dangerous than Covid-19. So will we soon see major progress in developing new antibiotics? It will be a long slog…
22 May 2020
Biotech firm's shares soar on hopes of a Covid-19 vaccine
Biotech firm's shares soar on hopes of a Covid-19 vaccine
Shares in biotech firm Moderna have rocketed after an early-stage trial of a drug showed promise. But they could soon return to earth. Matthew Partrid…
21 May 2020
Get your FREE guide to market crashes
What do past crashes teach us about this one? Subscribe to MoneyWeek now and get a free copy of the Little Book of Big Crashes, plus your first six magazine issues absolutely FREE
Look beyond Merck’s miracle cancer drug for profits
Look beyond Merck’s miracle cancer drug for profits
Keytruda, Merk’s cancer treatment, is a winner. But it’s not the only reason to be bullish on the pharma group.
18 May 2020
Three stocks to profit from the healthcare innovation revolution
Three stocks to profit from the healthcare innovation revolution
Anthony Ginsberg, manager of the HAN-GINS Indxx Healthcare Innovation UCITS ETF, picks three of his favourite healthcare stocks to buy now.
11 May 2020
Three biotech stocks to buy for healthy long-term returns
Three biotech stocks to buy for healthy long-term returns
Professional investor Marek Poszepczynki of the International Biotechnology Trust picks three biotech stocks with strong balance sheets that look well…
27 Apr 2020
Cash injection: join the hunt for a coronavirus vaccine
Cash injection: join the hunt for a coronavirus vaccine
Covid-19 has renewed interest in preventing the spread of viruses. But the appeal of this rapidly growing sub-sector of the pharmaceuticals market sho…
23 Apr 2020
Gilead's anti-viral expertise will stand it well
Gilead's anti-viral expertise will stand it well
There is far more to biotech giant Gilead Sciences than its potential treatment for Covid-19; it has expertise in anti-virals against a wide range of …
14 Apr 2020
Profit from treating peanut allergies
Profit from treating peanut allergies
Aimmune Therapeutics has produced the best treatment yet for children who have a peanut allergy.
14 Apr 2020
Gilead's takeover of Forty Seven should soothe shareholders' worries
Gilead's takeover of Forty Seven should soothe shareholders' worries
Gilean, the biopharma giant, is stocking up on potentially lucrative cancer drugs by snapping up smaller operators.
6 Mar 2020
Five funds to buy into biotech's healthy future
Five funds to buy into biotech's healthy future
The biotech sector has struggled over the past year, but it remains a solid long-term investment. Here are five good ways to buy in.
26 Nov 2019
The best way to play the biotech boom
The best way to play the biotech boom
Syncona is an unusual investment trust that invests in promising privately held biotech companies. It should be a core holding in any portfolio, says …
30 Jul 2019
How stem cells are changing the face of medicine
How stem cells are changing the face of medicine
We have only just started getting to grips with the vast life-saving potential of stem cells, the basic building blocks of the body. Dr Mike Tubbs exp…
26 Jul 2019
How to profit from the age of bespoke medicine
How to profit from the age of bespoke medicine
Doctors have traditionally approached diseases with a one-size-fits-all model. But advances in genetics and artificial intelligence are making medical…
11 Jul 2019
The drugs don’t work: stopping the spread of the superbugs
The drugs don’t work: stopping the spread of the superbugs
Antibiotic resistance could turn medical inconveniences into death sentences and become a bigger killer than cancer. Governments and pharmaceutical co…
11 Apr 2019
Immunotherapy: new hope in the battle against cancer
Immunotherapy: new hope in the battle against cancer
Immunotherapy is a burgeoning sector that heralds a breakthrough against the world’s second-most deadly disease. Dr Mike Tubbs explains how investors …
4 Apr 2019
Invest in helium, biotech, and UK small caps in 2019
Invest in helium, biotech, and UK small caps in 2019
We asked our contributors to choose their favourite investment ideas from around the world for this year and beyond. Here’s what they came up with.
27 Dec 2018
Investing in healthcare innovation
Investing in healthcare innovation
The Worldwide Healthcare Trust provides investors with access to exciting opportunities, says Max King.
19 Oct 2018